The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index; 11 of the 30 sources its claims cite were checked for support.
Native metabolomics identifies the rivulariapeptolide family of protease inhibitors
Open accessPublished version of a preprint
Abstract
The identity and biological activity of most metabolites still remain unknown. A bottleneck in the exploration of metabolite structures and pharmaceutical activities is the compound purification needed for bioactivity assignments and downstream structure elucidation. To enable bioactivity-focused compound identification from complex mixtures, we develop a scalable native metabolomics approach that integrates non-targeted liquid chromatography tandem mass spectrometry and detection of protein binding via native mass spectrometry. A native metabolomics screen for protease inhibitors from an environmental cyanobacteria community reveals 30 chymotrypsin-binding cyclodepsipeptides. Guided by the native metabolomics results, we select and purify five of these compounds for full structure elucidation via tandem mass spectrometry, chemical derivatization, and nuclear magnetic resonance spectroscopy as well as evaluation of their biological activities. These results identify rivulariapeptolides as a family of serine protease inhibitors with nanomolar potency, highlighting native metabolomics as a promising approach for drug discovery, chemical ecology, and chemical biology studies.
Overview
CoChat Summary
## TL;DR
The paper develops a “native metabolomics” workflow that combines LC-MS/MS with native MS protein-infused screening to find metabolites that bind a target protein directly from crude extracts. Applied to a marine cyanobacterial extract, it identified 30 chymotrypsin-binding cyclodepsipeptides and led to the discovery of the rivulariapeptolides as nanomolar serine protease inhibitors.
## Key findings
- A single 10-min LC-MS run of a Rivularia sp. cyanobacterial extract revealed more than 30 potential small molecule–protein complexes and 30 chymotrypsin-binding natural products.
- The workflow enabled isolation and structure elucidation of five compounds plus one derivative: rivulariapeptolides 1185, 1155, 1121, 989 and molassamide B.
- The purified compounds were confirmed as nanomolar chymotrypsin inhibitors; compound 1 (rivulariapeptolide 1185) was most potent against chymotrypsin with IC50 = 13.17 nM.
- A single ortho-bromination in the N-methyltyrosine moiety produced a 35-fold increase in potency for molassamide B (6) versus molassamide (5) against chymotrypsin (24.65 nM vs 862.60 nM); the paper also reports IC50 = 4.94 nM for compound 2 against elastase and IC50 = 5.42 nM for compound 6 against proteinase K.
## Methods
- Developed a native metabolomics workflow that pairs non-targeted LC-MS/MS with post-column protein infusion and native MS detection of protein-ligand complexes; the target protein was chymotrypsin.
- Screened a methanolic crude extract from an environmental cyanobacterial biofilm of Rivularia sp. collected in Puerto Rico; features were matched between native MS and metabolomics data by retention time and mass offset.
- Followed up by fractionation, preparative/semi-preparative HPLC, MS/MS, chemical derivatization, NMR, and fluorescence-based protease inhibition assays to determine structures and IC50 values.
- Data analysis used Xtract/FLASHDeconv, MZmine2.37, GNPS feature-based molecular networking, SIRIUS/ZODIAC, and CANOPUS.
## Limitations
- The authors state that the approach was used mainly as a first hypothesis-generating tool and that putative binders should be validated with orthogonal methods; absolute binding affinities and enzyme inhibition rates were not determined by native metabolomics alone.
- They note that the method’s suitability for lower-affinity protein-small molecule interactions and larger proteins remains to be characterized.
- Evident from the text: the workflow required careful optimization of buffer and instrument settings, and the paper relies on a single environmental sample/case study, so generality beyond the demonstrated system is not established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
10 Valid · 3 Not valid · 4 Not checked · 61 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Nevertheless, informed estimations can be made about relative binding affinities by fitting the intensity ratio of bound and unbound protein as a function of ligand concentration21,72.”
§ Native metabolomics identifies the rivulariapeptolide family of protease inhibitors > Discussion Here we describe the use of native metabolomics protein infusion MS to simultaneously detect protein-metabolite binding and annotate their molecular structures. This approach can be used for rapid screening of small molecule modulators for proteins of interest, directly from crude extracts. In our case study, we identified 30 chymotrypsin-binding natural products in a 10 min LC-MS run from a few µg of crude extract (not including downstream isolation and de novo structure elucidation). In comparison to flow-injection experiments (injection of crude extract in the native MS setup without column), we observed a strong signal decrease, most likely through collective ion suppression effects (Supplementary Fig. 3d, left panel). When injecting preincubated chymotrypsin-crude extract mixture into our system (Supplementary Fig. 3d, right panel) we observed a more acceptable signal response and several protein-metabolite complexes, which we attributed to molassamide B, a molassamide derivative, and rivulariapeptolide 1185. However, in comparison to native metabolomics, the number of putative binders observed was significantly lower, indicating that chromatographic separation is an important factor in the sensitivity of the approach. Most importantly, the chromatographic dimension is also essential for the unambiguous linking of binding information to MS/MS features which facilitates dereplication and downstream structure elucidation. Online Post-column complex formation by addition of metal binding partner has been used, to study carbohydrates67 and siderophores68, respectively, which we here expand to protein targets as binding partners. Initial tests with 12 proteins showed the accessibility of a wide range of protein targets by native metabolomics (Supplementary Fig. 46) as well as the need to optimize buffer concentrations and mass spectrometry settings. While this experiment highlights the accessibility of diverse proteins under native metabolomics conditions, we did not monitor ligand binding for these proteins. Since we did not assess binding properties with differentially affine ligands and proteins of different molecular weights, the suitability of our approach for studying protein-small molecule interactions of lower affinity and with larger proteins remains to be characterized. Still, we assume that native metabolomics is generalizable to other protein targets that are accessible via native ESI69–71 provided that they are available in large enough quantities. The amounts of protein needed for native metabolomics high-throughput screening are a few mg for a 24 h screen of 96 samples with a 10 min LC-MS method, which is achievable for many commercially available proteins or those coming from in-house heterologous protein expression.
What the sources say
- Supportedcites [21] Su, H. et al. Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharm. Sin. 41, 1167–1177 (2020). source
The Results section (‘Protein–ligand binding supported by ITC and ESI-MS’; page not provided) says the bound-to-unbound peak-intensity ratio indicates binding affinity and reports Kd values from plotting the bound-protein fraction against ligand concentration. The Methods section (‘Native-state mass spectrometry studies’; page not provided) confirms that intensities were measured across a series of ligand concentrations. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [72] Sun, J., Kitova, E. N., Wang, W. & Klassen, J. S. Method for distinguishing specific from nonspecific protein−ligand complexes in nanoelectrospray ionization mass spectrometry. Anal. Chem. 78, 3010–3018 (2006). source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Subsequently, we classified the MS/MS spectrum as indicative of a “cyclic depsipeptide” based on the classification with CANOPUS9.”
§ Native metabolomics identifies the rivulariapeptolide family of protease inhibitors > Results > Rivulariapeptolides, a family of new Ahp-cyclodepsipeptides The potential chymotrypsin-binder with the m/z 1186.6400, identified by native metabolomics, was next targeted for isolation and structure elucidation, using state-of-the-art high-resolution MS/MS and NMR approaches55 (see also Supplementary Methods). We first separated the Rivularia crude extract into four fractions of decreasing polarity via solid phase extraction. SMART NMR11 analysis was applied to the most hydrophilic fraction and all but one structure of the top 10 SMART results were predicted as cyclic depsipeptides (Fig. 3a, b and Supplementary Fig. 6), including 6 of the top 10 as Ahp-cyclodepsipeptides (three from marine filamentous cyanobacteria: somamide B, molassamide, lyngbyastatin 6)49,56–58. Complementarily, MS/MS-based molecular networking analysis of the Rivularia crude fractions assisted with the annotation of the known Ahp-peptides molassamide, kurahamide, and loggerpeptin A, along with several putatively new ones (Fig. 3a, b and Supplementary Fig. 7a)49,57,59. Next, the SIRIUS and ZODIAC tools10,60 were applied to determine the molecular formula of the chymotrypsin-binding feature, with exact mass m/z 1186.6400 [M + H]+, as C61H87N9O15 (0.5 ppm). Subsequently, we classified the MS/MS spectrum as indicative of a “cyclic depsipeptide” based on the classification with CANOPUS9. Further substructures of the molecule were predicted as benzene, hydroxy-benzene, and proline/N-acyl-pyrrolidine derivatives, as well as piperidinone/delta-lactam for the Ahp-family defining moiety (Fig. 3c and Supplementary Fig. 7b). To unambiguously determine the structure, we isolated m/z 1186.6400, named rivulariapeptolide 1185 (1), and performed 1D/2D NMR experiments and manual MS/MS interpretation (Fig. 3d, Supplementary Figs. 8–13, 43, and Supplementary Table 1). Subsequently, we targeted the isolation of further rivulariapeptolides by preparative HPLC, based on their protein-ligand complex ratios from the native metabolomics experiments as well as their relative abundance. In that way, we isolated and elucidated the planar structures of the rivulariapeptolides 1185, 1155, 1121, and 989 (1, 2, 3, 4) with the exact masses 1186.6400 [M + H]+ (C61H88N9O15, 0.5 ppm), 1156.5923 [M + H]+ (C59H82N9O15, − 0.2 ppm), 1122.6080 [M + H]+ (C56H84N9O15, − 0.1 ppm) and 989.4978 [M + H]+ (C50H69N8O13, − 0.1 ppm). In addition to rivulariapeptolides, we identified a new molassamide derivative that we termed “molassamide B” (6) with m/z 1041.3924 [M + H]+ (C48H66BrN8O13, −0.3 ppm), which is ortho-brominated (Supplementary Figs. 14–43 and Supplementary Tables 2, 3). The absolute configurations of the amino acids were determined by UHPLC-MS analysis of the acid hydrolysates of 2 and its pyridinium dichromate oxidation product and subsequent advanced Marfey’s analysis (Supplementary Fig. 44a). The analyses revealed L-configurations for all amino acids as is the case for other cyanobacterial Ahp-cyclodepsipeptides. The relative configuration of the stereocenters of the (3 S, 6 R)-Ahp-unit as well as the geometry of the double bond (Z-configuration) of the 2-amino-2-butenoic acid (Abu) moiety was determined by NOESY and HMBC NMR experiments (Supplementary Fig. 44b). Assuming that the other rivulariapeptolides (1, 3, 4) and molassamides (5 + 6) described here originate from the same biosynthetic nonribosomal peptide synthetase, they most probably also share the same backbone configuration. The highly comparable MS/MS and NMR data sets of compounds 1-6 (Supplementary Figs. 8–43 and Supplementary Tables 1–4) provide additional evidence that the discovered Ahp-cyclodepsipeptides from this study share the same configuration. Finally, the chymotrypsin inhibitory activities of the purified Ahp-cyclodepsipeptides 1-6 were assessed by specific biochemical assays and confirmed the results of the native metabolomic protein infusion MS experiments (Fig. 4). All six compounds were found to be nanomolar chymotrypsin inhibitors with compound 1 being the most potent (Fig. 4, IC50 = 13.17 nM). The newly described family of rivulariapeptolides is characterized by a rare (duplicated) N-butyrylated proline moiety in the side chain. Peptides 1-4 and 6 are among the six most potent natural chymotrypsin inhibitors from the compound class of Ahp-cyclodepsipeptides that have been reported to date36 (Supplementary Table 5). Intriguingly, a single ortho-bromination in the N-methyltyrosine moiety led to a 35-fold increase in potency for the new compound 6 (IC50 = 24.65 nM), when compared to the known compound 5 (IC50 = 862.60 nM). These promising results led us to test these six Ahp-cyclodepsipeptides against two other serine proteases, elastase and proteinase K. Elastase is produced in either the pancreas, for digestion of food, or by neutrophils for degradation of foreign proteins. Neutrophil elastase is a well-established drug target for the treatment of acute lung injury and acute respiratory distress syndrome61. Proteinase K is a fungal serine endopeptidase that is commonly used in molecular biology procedures62. This enzyme family plays important roles in the fungal infection of insects63 and mammals64. While 2 was found to be a potent elastase inhibitor (IC50 = 4.94 nM), 6 was discovered to be the most potent proteinase K inhibitor known to date (IC50 = 5.42 nM). The isolated compounds were docked by induced-fit, inside the binding pocket of alpha-chymotrypsin (PDBID 4Q2K), and all were found to have a similar binding mode (Supplementary Methods and Supplementary Fig. 45) that was revealed by crystal structures of Ahp-cyclodepsipeptides in complex with serine proteases65,66.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The observed Δ mass of 962.5 Da matches the mass of molassamide (962.4749 Da).”
§ Native metabolomics identifies the rivulariapeptolide family of protease inhibitors > Results > Development of the native metabolomics approach
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Intriguingly, a single ortho-bromination in the N-methyltyrosine moiety led to a 35-fold increase in potency for the new compound 6 (IC50 = 24.65 nM), when compared to the known compound 5 (IC50 = 862.60 nM).”
§ Native metabolomics identifies the rivulariapeptolide family of protease inhibitors > Results > Rivulariapeptolides, a family of new Ahp-cyclodepsipeptides The potential chymotrypsin-binder with the m/z 1186.6400, identified by native metabolomics, was next targeted for isolation and structure elucidation, using state-of-the-art high-resolution MS/MS and NMR approaches55 (see also Supplementary Methods). We first separated the Rivularia crude extract into four fractions of decreasing polarity via solid phase extraction. SMART NMR11 analysis was applied to the most hydrophilic fraction and all but one structure of the top 10 SMART results were predicted as cyclic depsipeptides (Fig. 3a, b and Supplementary Fig. 6), including 6 of the top 10 as Ahp-cyclodepsipeptides (three from marine filamentous cyanobacteria: somamide B, molassamide, lyngbyastatin 6)49,56–58. Complementarily, MS/MS-based molecular networking analysis of the Rivularia crude fractions assisted with the annotation of the known Ahp-peptides molassamide, kurahamide, and loggerpeptin A, along with several putatively new ones (Fig. 3a, b and Supplementary Fig. 7a)49,57,59. Next, the SIRIUS and ZODIAC tools10,60 were applied to determine the molecular formula of the chymotrypsin-binding feature, with exact mass m/z 1186.6400 [M + H]+, as C61H87N9O15 (0.5 ppm). Subsequently, we classified the MS/MS spectrum as indicative of a “cyclic depsipeptide” based on the classification with CANOPUS9. Further substructures of the molecule were predicted as benzene, hydroxy-benzene, and proline/N-acyl-pyrrolidine derivatives, as well as piperidinone/delta-lactam for the Ahp-family defining moiety (Fig. 3c and Supplementary Fig. 7b). To unambiguously determine the structure, we isolated m/z 1186.6400, named rivulariapeptolide 1185 (1), and performed 1D/2D NMR experiments and manual MS/MS interpretation (Fig. 3d, Supplementary Figs. 8–13, 43, and Supplementary Table 1). Subsequently, we targeted the isolation of further rivulariapeptolides by preparative HPLC, based on their protein-ligand complex ratios from the native metabolomics experiments as well as their relative abundance. In that way, we isolated and elucidated the planar structures of the rivulariapeptolides 1185, 1155, 1121, and 989 (1, 2, 3, 4) with the exact masses 1186.6400 [M + H]+ (C61H88N9O15, 0.5 ppm), 1156.5923 [M + H]+ (C59H82N9O15, − 0.2 ppm), 1122.6080 [M + H]+ (C56H84N9O15, − 0.1 ppm) and 989.4978 [M + H]+ (C50H69N8O13, − 0.1 ppm). In addition to rivulariapeptolides, we identified a new molassamide derivative that we termed “molassamide B” (6) with m/z 1041.3924 [M + H]+ (C48H66BrN8O13, −0.3 ppm), which is ortho-brominated (Supplementary Figs. 14–43 and Supplementary Tables 2, 3). The absolute configurations of the amino acids were determined by UHPLC-MS analysis of the acid hydrolysates of 2 and its pyridinium dichromate oxidation product and subsequent advanced Marfey’s analysis (Supplementary Fig. 44a). The analyses revealed L-configurations for all amino acids as is the case for other cyanobacterial Ahp-cyclodepsipeptides. The relative configuration of the stereocenters of the (3 S, 6 R)-Ahp-unit as well as the geometry of the double bond (Z-configuration) of the 2-amino-2-butenoic acid (Abu) moiety was determined by NOESY and HMBC NMR experiments (Supplementary Fig. 44b). Assuming that the other rivulariapeptolides (1, 3, 4) and molassamides (5 + 6) described here originate from the same biosynthetic nonribosomal peptide synthetase, they most probably also share the same backbone configuration. The highly comparable MS/MS and NMR data sets of compounds 1-6 (Supplementary Figs. 8–43 and Supplementary Tables 1–4) provide additional evidence that the discovered Ahp-cyclodepsipeptides from this study share the same configuration. Finally, the chymotrypsin inhibitory activities of the purified Ahp-cyclodepsipeptides 1-6 were assessed by specific biochemical assays and confirmed the results of the native metabolomic protein infusion MS experiments (Fig. 4). All six compounds were found to be nanomolar chymotrypsin inhibitors with compound 1 being the most potent (Fig. 4, IC50 = 13.17 nM). The newly described family of rivulariapeptolides is characterized by a rare (duplicated) N-butyrylated proline moiety in the side chain. Peptides 1-4 and 6 are among the six most potent natural chymotrypsin inhibitors from the compound class of Ahp-cyclodepsipeptides that have been reported to date36 (Supplementary Table 5). Intriguingly, a single ortho-bromination in the N-methyltyrosine moiety led to a 35-fold increase in potency for the new compound 6 (IC50 = 24.65 nM), when compared to the known compound 5 (IC50 = 862.60 nM). These promising results led us to test these six Ahp-cyclodepsipeptides against two other serine proteases, elastase and proteinase K. Elastase is produced in either the pancreas, for digestion of food, or by neutrophils for degradation of foreign proteins. Neutrophil elastase is a well-established drug target for the treatment of acute lung injury and acute respiratory distress syndrome61. Proteinase K is a fungal serine endopeptidase that is commonly used in molecular biology procedures62. This enzyme family plays important roles in the fungal infection of insects63 and mammals64. While 2 was found to be a potent elastase inhibitor (IC50 = 4.94 nM), 6 was discovered to be the most potent proteinase K inhibitor known to date (IC50 = 5.42 nM). The isolated compounds were docked by induced-fit, inside the binding pocket of alpha-chymotrypsin (PDBID 4Q2K), and all were found to have a similar binding mode (Supplementary Methods and Supplementary Fig. 45) that was revealed by crystal structures of Ahp-cyclodepsipeptides in complex with serine proteases65,66.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Next, the SIRIUS and ZODIAC tools10,60 were applied to determine the molecular formula of the chymotrypsin-binding feature, with exact mass m/z 1186.6400 [M + H]+, as C61H87N9O15 (0.5 ppm).”
§ Native metabolomics identifies the rivulariapeptolide family of protease inhibitors > Results > Rivulariapeptolides, a family of new Ahp-cyclodepsipeptides The potential chymotrypsin-binder with the m/z 1186.6400, identified by native metabolomics, was next targeted for isolation and structure elucidation, using state-of-the-art high-resolution MS/MS and NMR approaches55 (see also Supplementary Methods). We first separated the Rivularia crude extract into four fractions of decreasing polarity via solid phase extraction. SMART NMR11 analysis was applied to the most hydrophilic fraction and all but one structure of the top 10 SMART results were predicted as cyclic depsipeptides (Fig. 3a, b and Supplementary Fig. 6), including 6 of the top 10 as Ahp-cyclodepsipeptides (three from marine filamentous cyanobacteria: somamide B, molassamide, lyngbyastatin 6)49,56–58. Complementarily, MS/MS-based molecular networking analysis of the Rivularia crude fractions assisted with the annotation of the known Ahp-peptides molassamide, kurahamide, and loggerpeptin A, along with several putatively new ones (Fig. 3a, b and Supplementary Fig. 7a)49,57,59. Next, the SIRIUS and ZODIAC tools10,60 were applied to determine the molecular formula of the chymotrypsin-binding feature, with exact mass m/z 1186.6400 [M + H]+, as C61H87N9O15 (0.5 ppm). Subsequently, we classified the MS/MS spectrum as indicative of a “cyclic depsipeptide” based on the classification with CANOPUS9. Further substructures of the molecule were predicted as benzene, hydroxy-benzene, and proline/N-acyl-pyrrolidine derivatives, as well as piperidinone/delta-lactam for the Ahp-family defining moiety (Fig. 3c and Supplementary Fig. 7b). To unambiguously determine the structure, we isolated m/z 1186.6400, named rivulariapeptolide 1185 (1), and performed 1D/2D NMR experiments and manual MS/MS interpretation (Fig. 3d, Supplementary Figs. 8–13, 43, and Supplementary Table 1). Subsequently, we targeted the isolation of further rivulariapeptolides by preparative HPLC, based on their protein-ligand complex ratios from the native metabolomics experiments as well as their relative abundance. In that way, we isolated and elucidated the planar structures of the rivulariapeptolides 1185, 1155, 1121, and 989 (1, 2, 3, 4) with the exact masses 1186.6400 [M + H]+ (C61H88N9O15, 0.5 ppm), 1156.5923 [M + H]+ (C59H82N9O15, − 0.2 ppm), 1122.6080 [M + H]+ (C56H84N9O15, − 0.1 ppm) and 989.4978 [M + H]+ (C50H69N8O13, − 0.1 ppm). In addition to rivulariapeptolides, we identified a new molassamide derivative that we termed “molassamide B” (6) with m/z 1041.3924 [M + H]+ (C48H66BrN8O13, −0.3 ppm), which is ortho-brominated (Supplementary Figs. 14–43 and Supplementary Tables 2, 3). The absolute configurations of the amino acids were determined by UHPLC-MS analysis of the acid hydrolysates of 2 and its pyridinium dichromate oxidation product and subsequent advanced Marfey’s analysis (Supplementary Fig. 44a). The analyses revealed L-configurations for all amino acids as is the case for other cyanobacterial Ahp-cyclodepsipeptides. The relative configuration of the stereocenters of the (3 S, 6 R)-Ahp-unit as well as the geometry of the double bond (Z-configuration) of the 2-amino-2-butenoic acid (Abu) moiety was determined by NOESY and HMBC NMR experiments (Supplementary Fig. 44b). Assuming that the other rivulariapeptolides (1, 3, 4) and molassamides (5 + 6) described here originate from the same biosynthetic nonribosomal peptide synthetase, they most probably also share the same backbone configuration. The highly comparable MS/MS and NMR data sets of compounds 1-6 (Supplementary Figs. 8–43 and Supplementary Tables 1–4) provide additional evidence that the discovered Ahp-cyclodepsipeptides from this study share the same configuration. Finally, the chymotrypsin inhibitory activities of the purified Ahp-cyclodepsipeptides 1-6 were assessed by specific biochemical assays and confirmed the results of the native metabolomic protein infusion MS experiments (Fig. 4). All six compounds were found to be nanomolar chymotrypsin inhibitors with compound 1 being the most potent (Fig. 4, IC50 = 13.17 nM). The newly described family of rivulariapeptolides is characterized by a rare (duplicated) N-butyrylated proline moiety in the side chain. Peptides 1-4 and 6 are among the six most potent natural chymotrypsin inhibitors from the compound class of Ahp-cyclodepsipeptides that have been reported to date36 (Supplementary Table 5). Intriguingly, a single ortho-bromination in the N-methyltyrosine moiety led to a 35-fold increase in potency for the new compound 6 (IC50 = 24.65 nM), when compared to the known compound 5 (IC50 = 862.60 nM). These promising results led us to test these six Ahp-cyclodepsipeptides against two other serine proteases, elastase and proteinase K. Elastase is produced in either the pancreas, for digestion of food, or by neutrophils for degradation of foreign proteins. Neutrophil elastase is a well-established drug target for the treatment of acute lung injury and acute respiratory distress syndrome61. Proteinase K is a fungal serine endopeptidase that is commonly used in molecular biology procedures62. This enzyme family plays important roles in the fungal infection of insects63 and mammals64. While 2 was found to be a potent elastase inhibitor (IC50 = 4.94 nM), 6 was discovered to be the most potent proteinase K inhibitor known to date (IC50 = 5.42 nM). The isolated compounds were docked by induced-fit, inside the binding pocket of alpha-chymotrypsin (PDBID 4Q2K), and all were found to have a similar binding mode (Supplementary Methods and Supplementary Fig. 45) that was revealed by crystal structures of Ahp-cyclodepsipeptides in complex with serine proteases65,66.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
34 more claims
Create a free account to see all 78 claims and every source verdict.
- Probably not a substantial claim. 19
- It may state two separate claims as one. 22
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The full structures of four new 3-amino-6-hydroxy-2-piperidone (Ahp)-cyclodepsipeptides were determined using in silico structure prediction from high resolution MS and MS/MS data along with 1D and 2D NMR analysis (Fig. 4E).”
From Connecting metabolome and phenotype: recent advances in functional metabolomics tools for the identification of bioactive natural products (2024) · cites this paper as [83]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This approach has been central for the discovery of the rivulariapeptolides, a family of potent chymotrypsin binders from Rivularia sp., a marine cyanobacterium collected at Carlos Rosario Beach in Puerto Rico.83”
From Connecting metabolome and phenotype: recent advances in functional metabolomics tools for the identification of bioactive natural products (2024) · cites this paper as [83]
Citations
Cites
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
Newman, D. J., & Cragg, G. M. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b01285 · Cited by 7,015
Sumner, L. W., Amberg, A., Barrett, D., Beale, M. H., Beger, R., Daykin, C. A., Fan, T. W.-M., Fiehn, O., Goodacre, R., Griffin, J. L., et al. (2007) · Metabolomics · doi:10.1007/s11306-007-0082-2 · Cited by 5,368
Identifying Small Molecules via High Resolution Mass Spectrometry: Communicating Confidence
Schymanski, E. L., Jeon, J., Gulde, R., Fenner, K., Ruff, M., Singer, H. P., & Hollender, J. (2014) · Environmental Science & Technology · doi:10.1021/es5002105 · Cited by 4,519
SIRIUS 4: a rapid tool for turning tandem mass spectra into metabolite structure information
Dührkop, K., Fleischauer, M., Ludwig, M., Aksenov, A. A., Melnik, A. V., Meusel, M., Dorrestein, P. C., Rousu, J., & Böcker, S. (2019) · Nature Methods · doi:10.1038/s41592-019-0344-8 · Cited by 2,060
Self-citationAn oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., et al. (2021) · Science · doi:10.1126/science.abl4784 · Cited by 2,033
Identification of bioactive metabolites using activity metabolomics
Rinschen, M. M., Ivanisevic, J., Giera, M., & Siuzdak, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0108-4 · Cited by 1,008
Systematic classification of unknown metabolites using high-resolution fragmentation mass spectra
Dührkop, K., Nothias, L.-F., Fleischauer, M., Reher, R., Ludwig, M., Hoffmann, M. A., Petras, D., Gerwick, W. H., Rousu, J., Dorrestein, P. C., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-0740-8 · Cited by 860
Self-citationNative Mass Spectrometry: What is in the Name?
Leney, A. C., & Heck, A. J. R. (2017) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-016-1545-3 · Cited by 602
Retrospective analysis of natural products provides insights for future discovery trends
Pye, C. R., Bertin, M. J., Lokey, R. S., Gerwick, W. H., & Linington, R. G. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614680114 · Cited by 534
Self-citationAnti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients
Su, H.-X., Yao, S., Zhao, W.-F., Li, M.-J., Liu, J., Shang, W.-J., Xie, H., Ke, C.-Q., Hu, H.-C., Gao, M.-N., et al. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0483-6 · Cited by 456
Research works printed but not linked: 1
- Anderson, J., Schiffer, C., Lee, S.-K. & Swanstrom, R. in Antiviral Strategies (eds. Kräusslich, H.-G. & Bartenschlager, R.) (Springer, 2009).
Cited by
Artificial intelligence for natural product drug discovery
Mullowney, M. W., Duncan, K. R., Elsayed, S. S., Garg, N., van der Hooft, J. J. J., Martin, N. I., Meijer, D., Terlouw, B. R., Biermann, F., Blin, K., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00774-7 · Cited by 460
“The structures of the rivulariapeptolides and symplocolide A were predicted from complex microbial extracts using a convolutional neural network 28,152 .”
BackgroundMethodSelf-citationHellinger, R., Sigurdsson, A., Wu, W., Romanova, E. V., Li, L., Sweedler, J. V., Süßmuth, R. D., & Gruber, C. W. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00205-2 · Cited by 147
Shah, A. K. P. M., Walter, A., Ottosson, F. A., Russo, F., Navarro-Díaz, M., Boldt, J., Kalinski, J. J., Kontou, E. E., Elofson, J., Polyzois, A., et al. (2024) · Nature Protocols · doi:10.1038/s41596-024-01046-3 · Cited by 115
Self-citationArtificial intelligence in microbial natural product drug discovery: current and emerging role
Sahayasheela, V. J., Lankadasari, M. B., Dan, V. M., Dastager, S. G., Pandian, G. N., & Sugiyama, H. (2022) · Natural Product Reports · doi:10.1039/d2np00035k · Cited by 87
A Survey of Recently Discovered Naturally Occurring Organohalogen Compounds
Gribble, G. W. (2024) · Journal of Natural Products · doi:10.1021/acs.jnatprod.3c00803 · Cited by 73
Metadata
- Authors
- Reher, R., Aron, A. T., Fajtová, P., Stincone, P., Wagner, B., Pérez-Lorente, A. I., Liu, C., Shalom, I. Y. B., Bittremieux, W., Wang, M., Jeong, K., Matos-Hernandez, M. L., Alexander, K. L., Caro-Diaz, E. J., Naman, C. B., Scanlan, J. H. W., Hochban, P. M. M., Diederich, W. E., Molina-Santiago, C., Romero, D., Selim, K. A., Sass, P., Brötz-Oesterhelt, H., Hughes, C. C., Dorrestein, P. C., O’Donoghue, A. J., Gerwick, W. H., & Petras, D.
- Affiliations
- Scripps Institution of Oceanography (US)
- University of California San Diego (US)
- University of Tübingen (DE)
- Ningbo University (CN)
- Philipps University of Marburg (DE)
- Consejo Superior de Investigaciones Científicas (ES)
- German Center for Infection Research (DE)
- Corresponding author
- Gerwick, William H.
- Petras, Daniel
- ORCID
- Reher, Raphael
- Aron, Allegra T.
- Fajtová, Pavla
- Stincone, Paolo
- Wagner, Berenike
- Liu, Chenxi
- Shalom, Ido Y. Ben
- Bittremieux, Wout
- Wang, Mingxun
- Jeong, Kyowon
- Matos-Hernandez, Marie L.
- Alexander, Kelsey L.
- Caro-Diaz, Eduardo J.
- Naman, C. Benjamin
- Hochban, Phil M. M.
- Diederich, Wibke E.
- Molina-Santiago, Carlos
- Romero, Diego
- Selim, Khaled A.
- Sass, Peter
- Brötz-Oesterhelt, Heike
- Hughes, Chambers C.
- Dorrestein, Pieter C.
- O’Donoghue, Anthony J.
- Gerwick, William H.
- Petras, Daniel
- Venue
- Nature Communications
- Published
- 2022-08-08
- Volume
- 13
- Issue
- 1
- Pages
- 4619-4619
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC9358669
- OpenAlex
- W4290648675
- Cited by
- 53
- References
- 72
- Citations by year
- 2026: 5 · 2025: 18 · 2024: 11 · 2023: 15 · 2022: 3
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (acceptedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Deutsche Forschungsgemeinschaft (EXC 2124)
- Topics
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Physical Sciences › Chemistry › Spectroscopy › Mass Spectrometry Techniques and Applications
- Keywords
- protease inhibitors, serine protease inhibitors, cyclodepsipeptides, native mass spectrometry, cyanobacteria, compound purification, structure elucidation, chemical ecology, drug discovery
- MeSH terms
- Chromatography, Liquid, Magnetic Resonance Spectroscopy, Protease Inhibitors, Tandem Mass Spectrometry, Metabolomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Native metabolomics identifies the rivulariapeptolide family of protease inhibitors. https://app.cochat.ai/papers/10.1038/s41467-022-32016-6
- The paper
- Reher, R., Aron, A. T., Fajtová, P., Stincone, P., Wagner, B., Pérez-Lorente, A. I., Liu, C., Shalom, I. Y. B., Bittremieux, W., Wang, M., Jeong, K., Matos-Hernandez, M. L., Alexander, K. L., Caro-Diaz, E. J., Naman, C. B., Scanlan, J. H. W., Hochban, P. M. M., Diederich, W. E., Molina-Santiago, C., . . . Petras, D. (2022). Native metabolomics identifies the rivulariapeptolide family of protease inhibitors. Nature Communications. https://doi.org/10.1038/s41467-022-32016-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.